000155422 001__ 155422
000155422 005__ 20210129214105.0
000155422 0247_ $$2doi$$a10.1007/s11060-014-1594-z
000155422 0247_ $$2WOS$$aWOS:000345286700028
000155422 037__ $$aFZJ-2014-04588
000155422 082__ $$a610
000155422 1001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b0$$eCorresponding Author$$ufzj
000155422 245__ $$aLetter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]
000155422 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2014
000155422 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1416471104_16336
000155422 3367_ $$2DataCite$$aOutput Types/Journal article
000155422 3367_ $$00$$2EndNote$$aJournal Article
000155422 3367_ $$2BibTeX$$aARTICLE
000155422 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155422 3367_ $$2DRIVER$$aarticle
000155422 520__ $$ao the Editor,We have read with interest the review by Ryken et al. about the role of imaging in the management of progressive glioblastoma [1]. In general, we agree with this review but we cannot support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify progression of glioblastoma is not recommendable.The authors have considered PET using the amino acid tracer 11C-methyl-l-methionine (MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short half-life of 11C (20.4 min). In recent years, the clinical application of 18F-labeled amino acids such as O-(2-18F-fluoroethyl)-l-tyrosine (FET) or 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18F label (half-life, 109.8 min) [2]. FET can be produced with high yields similar to the widely used FDG and distributed in a satellite concept [3]. In Europe, MET PET has been replaced in many centers by the more convenie ...
000155422 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000155422 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000155422 7001_ $$0P:(DE-HGF)0$$aTonn, J. C.$$b1
000155422 7001_ $$0P:(DE-HGF)0$$aWeller, M.$$b2
000155422 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b3$$ufzj
000155422 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-014-1594-z$$n3$$p665-666$$tJournal of neuro-oncology$$v120$$x0167-594x$$y2014
000155422 8564_ $$uhttps://juser.fz-juelich.de/record/155422/files/FZJ-2014-04588.pdf$$yRestricted
000155422 909CO $$ooai:juser.fz-juelich.de:155422$$pVDB
000155422 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000155422 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000155422 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bPOF III$$lKey Technologies$$vDecoding the Human Brain$$x0
000155422 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000155422 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000155422 9141_ $$y2014
000155422 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000155422 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000155422 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000155422 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000155422 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000155422 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000155422 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000155422 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000155422 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000155422 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000155422 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000155422 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000155422 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000155422 980__ $$ajournal
000155422 980__ $$aVDB
000155422 980__ $$aI:(DE-Juel1)INM-3-20090406
000155422 980__ $$aI:(DE-Juel1)INM-4-20090406
000155422 980__ $$aUNRESTRICTED
000155422 981__ $$aI:(DE-Juel1)INM-4-20090406